Annual report pursuant to Section 13 and 15(d)

Iloperidone Sublicense to Novartis Pharma AG (Details Textual)

v2.4.0.8
Iloperidone Sublicense to Novartis Pharma AG (Details Textual) (Novartis [Member])
12 Months Ended
Dec. 31, 2013
Minimum [Member]
 
Operating Leased Assets [Line Items]  
Percentage of next slab of annual sales for calculating net royalty 8.00%
Maximum [Member]
 
Operating Leased Assets [Line Items]  
Percentage of next slab of annual sales for calculating net royalty 10.00%